Activity of antifungal agents alone and in combination against echinocandin-susceptible and -resistant Candida parapsilosis strains

Rev Iberoam Micol. 2019 Jan-Mar;36(1):44-47. doi: 10.1016/j.riam.2018.07.007. Epub 2019 Jan 26.

Abstract

Background: Candida parapsilosis may acquire resistance to echinocandins, a fact that prompts the search for new therapeutic options.

Aims: The present study aimed to evaluate the in vitro activity of antifungal agents, alone and in combination, against four groups of C. parapsilosis strains: (1) echinocandin-susceptible (ES) clinical isolates (MIC ≤ 2μg/ml), (2) anidulafungin-resistant strains (MIC ≥ 8μg/ml), (3) caspofungin-resistant strains (MIC ≥ 8μg/ml), and (4) micafungin-resistant strains (MIC ≥ 8μg/ml).

Methods: Antifungal interactions were evaluated by a checkerboard micro-dilution method. The determination of the MIC to each drug for every isolate according to the Clinical and Laboratory Standards Institute documents M27 (2017) and M60 (2017) was also done.

Results: The echinocandins-resistant (ER) strains showed higher MICs to the tested antifungals than the ES strains, except for amphotericin B, for which the ER groups remained susceptible.

Conclusions: Most combinations showed indifferent interactions. The use of monotherapy still seems to be the best option. As resistance to echinocandins is an emergent phenomenon, further studies are required to provide clearer information on the susceptibility differences between strains to these antifungal agents.

Keywords: Antifungal drug resistance; Antifungals; Antifúngicos; Candida parapsilosis; Echinocandins; Equinocandinas; Resistencia a los antifúngicos.

MeSH terms

  • Antifungal Agents / pharmacology*
  • Candida parapsilosis / classification
  • Candida parapsilosis / drug effects*
  • Drug Resistance, Fungal
  • Drug Therapy, Combination
  • Echinocandins / pharmacology*
  • Microbial Sensitivity Tests

Substances

  • Antifungal Agents
  • Echinocandins